Drug Status Report

**Drug**: Xiangsha Hewei

**Drug Name Status**: Xiangsha Hewei is the brand name.

Xiangsha Hewei is a herbal supplement used in traditional Chinese medicine (TCM) and consists of *Rhizoma Atractylodis Marcococephalae* and *Radix Aucklandiae Lappae* as its primary active ingredients. Xiangsha Hewei is used for the treatment of gastroenteric conditions such as the loss of appetite, heartburn, flatulence, vomiting and diarrhea.

*Rhizoma Atractylodis Marcococephalae*, belongs to the *Atractylodes* genus and is more commonly known as *A. macrocephala*. In TCM, the plant is known ‘Bai Zhu’ and is believed to be useful for treating gastroenteric conditions and disorders of the spleen\(^1\). A number of sesquiterpenoid lactones have been identified in *A. macrocephala* and which demonstrate anti-inflammatory and anti-cancer properties\(^1\). Recently, biatractylolide was also shown to display inotropic and chronotropic effects\(^2\).

![Biatractylolide](image)

*Radix Aucklandiae Lappae*, known in TCM as “Mu Xiang”, is used to aid digestion and to treat digestive disorders\(^3\)^4. The herb was recently found to contain a variety of essential oils that are believed to be the primary bioactive compounds in *Radix Aucklandiae Lappae*\(^4\).

Canadian Status: Xiangsha Hewei is not listed in the CDSA and does not contain any substances that are similar to those listed in the Schedules to the CDSA.

---


\(^3\)http://acupunctureandphytotherapy.com/mu-xiang-radix-aucklandiae-lappae-chinese-phytotherapy/

Recommendation: Xiangsha Hewei is not included in any of the Schedules to the CDSA and is not considered a controlled substance.

January 13th 2010.